PLx Pharma Inc.'s VAZALORE to be Available in over 8,000 CVS Stores Shortly

MedTech Outlook | Wednesday, August 11, 2021

Three stock-keeping units (SKUs) of VAZALORE will be available later this month.

FREMONT, CA: PLx Pharma Inc., a specialty pharmaceutical company on developing more effective and safer products through the use of its clinically validated and patent-protected PLxGuard drug delivery platform, with its lead products VAZALORE 325 mg and VAZALORE 81 mg (referred to together as VAZALORE), today announces that three stock-keeping units (SKUs) of VAZALORE, the first and only U.S. Food and Drug Administration (FDA) approved liquid-filled aspirin capsules, will be available in nearly 8,000 CVS stores later this month.

CVS, a renowned health solutions firm, is prepping its retail space in many of its shops with Coming Soon signs and shelf trays. This includes all three VAZALORE SKUs: 81 mg/12 counts, 81 mg/30 counts, and 325 mg/30 counts.

“As we continue to execute the launch of VAZALORE, we are excited that CVS has committed to placing our innovative aspirin product in its stores nationwide. CVS’ focus on the patient is well aligned with our mission in providing access to VAZALORE for millions of patients,” states Natasha Giordano, Chief Executive Officer of PLx.

CVS accompanies Walmart, Walgreens, Rite Aid, and several other retailers in announcing the nationwide launch of VAZALORE, the first and only liquid-filled aspirin capsules approved by the FDA.

VAZALORE is an FDA-approved liquid-filled aspirin capsule that provides faster, more reliable and predictable platelet inhibition than enteric-coated aspirin to patients with vascular disease and diabetic patients who are candidates for aspirin therapy based on physician recommendation. Additionally, it decreases the incidence of stomach erosions and ulcers compared to immediate-release aspirin, which is frequently prescribed in an acute environment.